Is Prazepam 10mg tablets a controlled drug in the UK?

Yes, Prazepam 10mg tablets is classified as Schedule 4 (CD Benz) under the UK Misuse of Drugs Regulations. This means there are special legal requirements for prescribing, dispensing, and storing this medicine. (Source: NHS dm+d, UK Misuse of Drugs Regulations 2001)

What should I avoid while taking Prazepam 10mg tablets?

Avoid alcohol. Avoid grapefruit products. Limit caffeine intake. (Source: DrugBank, licensed under CC BY-NC 4.0)

Do I need a prescription for Prazepam 10mg tablets?

Prazepam 10mg tablets is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Prazepam 10mg tablets?

Prazepam 10mg tablets is the generic name. It is available under brand names including: Centrax 10mg tablets. (Source: NHS dm+d — Actual Medicinal Products)

Prazepam 10mg tablets

Prescription only

Requires a prescription from a doctor or prescriber

Tablet

10mg

Oral

Prazepam is a benzodiazepine that is used in the treatment of anxiety disorders.

Active ingredients:

Prazepam

CD Schedule 4

Minimal controls; includes benzodiazepines and anabolic steroids

details

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC N05BA11

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Check interactions for Prazepam

1 safety notice

Schedule 4

Legal requirements and restrictions

Benzodiazepines and similar medicines. Subject to minimal controlled drug requirements.

Legal requirements

Prescriptions valid for 28 days
No controlled drugs register required
No safe custody requirements
Record keeping requirements for imports/exports

Other medicines in this category

Diazepam, Lorazepam, Nitrazepam, Zolpidem, Zopiclone

View full UK controlled drugs list

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Prazepam

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Prazepam

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

1 branded products available

1 productsShow details

1 products

Possibly available on the UK marketRestricted supplyDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Prazepam on the MHRA register

Centrax 10mg tablets

Imported (Ireland)

None

Imported

Source: NHS dm+dOGL 3.0

Updated about 1 month ago(1 Mar 2026)

Therapeutically similar medicines

10 similarShow details

Diazepam 2mg/5ml oral suspension sugar free

Oral suspension

2mg/5ml

Same therapeutic group

Clobazam 20mg tablets

Tablet

20mg

Same therapeutic group

Lorazepam 250microgram tablets

Tablet

Same therapeutic group

Lorazepam 4mg/1ml solution for injection vials

Injection

4mg/1ml

Same therapeutic group

Lorazepam 2mg/1ml solution for injection cartridges

Injection

2mg/1ml

Same therapeutic group

Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

Clinical guidelines and formulary information

British National Formulary

Prazepam

BNF

Drug monograph — bnf.nice.org.uk

Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Show details

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & product information

Official product databases and supply status monitoring

Shortages info

NHS Specialist Pharmacy Service (SPS)

emc product search

Discontinuations & alternatives for Prazepam

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.

Codes for healthcare professionals and prescribing systems

Show details

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

32856811000001103

dm+d ID

32856811000001103

VTM (Virtual Therapeutic Moiety)

777300009

VMP (Virtual Medicinal Product)

32856811000001103

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

N05BA11

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Show details

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

1 found

Half-life

36-200 hours

Mechanism

Prazepam is believed to stimulate GABA receptors in the ascending reticular activating system.

Food interactions

4 warnings

Human targets

3 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Half-life

36-200 hours

36-200 hours

Metabolism

Hepatic.

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Illicit

Small molecule

About this compound

Prazepam is a benzodiazepine that is used in the treatment of anxiety disorders. It is a schedule IV drug in the U.S.

Properties:

solid

Avg. mass: 324.80 Da

DrugBank indication

For the treatment of anxiety disorders.

Also known as(69)

Prazepam

Prazepamum

GABA(A) receptor subunit alpha-1

GABAAR subunit alpha-1

GABA(A) receptor subunit alpha-2

GABAAR subunit alpha-2

GABA(A) receptor subunit alpha-3

GABAAR subunit alpha-3

Dosage forms(5)

Tablet (Oral) — 10 mg/1

Tablet (Oral) — 20 mg

Solution / drops (Oral)

Tablet (Oral)

Tablet (Oral) — 10 MG

Molecular properties(18)

Drug interactions(801)

Known interactions with other medications. Always consult a healthcare professional.

Buprenorphine

Moderate

DB00921

Prazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.

Check this interaction

Doxylamine

Moderate

DB00366

Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Prazepam.

Check this interaction

Dronabinol

Moderate

DB00470

Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Prazepam.

Check this interaction

Droperidol

Moderate

DB00450

Droperidol may increase the central nervous system depressant (CNS depressant) activities of Prazepam.

Check this interaction

Hydrocodone

Moderate

DB00956

Prazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.

Check this interaction

Hydroxyzine

Moderate

DB00557

Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Prazepam.

Check this interaction

Magnesium sulfate

Moderate

DB00653

The therapeutic efficacy of Prazepam can be increased when used in combination with Magnesium sulfate.

Check this interaction

Methotrimeprazine

Moderate

DB01403

Prazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.

Check this interaction

Metyrosine

Moderate

DB00765

Prazepam may increase the sedative activities of Metyrosine.

Check this interaction

Minocycline

Moderate

DB01017

Minocycline may increase the central nervous system depressant (CNS depressant) activities of Prazepam.

Check this interaction

Mirtazapine

Moderate

DB00370

Prazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.

Check this interaction

Nabilone

Moderate

DB00486

Nabilone may increase the central nervous system depressant (CNS depressant) activities of Prazepam.

Check this interaction

Orphenadrine

Moderate

DB01173

Prazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.

Check this interaction

Paraldehyde

Moderate

DB09117

Prazepam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.

Check this interaction

Perampanel

Moderate

DB08883

Perampanel may increase the central nervous system depressant (CNS depressant) activities of Prazepam.

Check this interaction

Pramipexole

Moderate

DB00413

Prazepam may increase the sedative activities of Pramipexole.

Check this interaction

Ropinirole

Moderate

DB00268

Prazepam may increase the sedative activities of Ropinirole.

Check this interaction

Rotigotine

Moderate

DB05271

Prazepam may increase the sedative activities of Rotigotine.

Check this interaction

Rufinamide

Unknown severity

DB06201

The risk or severity of adverse effects can be increased when Rufinamide is combined with Prazepam.

Check this interaction

Suvorexant

Moderate

DB09034

Prazepam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.

Check this interaction

Tapentadol

Moderate

DB06204

Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Prazepam.

Check this interaction

Thalidomide

Moderate

DB01041

Prazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.

Check this interaction

Zolpidem

Moderate

DB00425

Prazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.

Check this interaction

Clozapine

Unknown severity

DB00363

The risk or severity of adverse effects can be increased when Prazepam is combined with Clozapine.

Check this interaction

Methadone

Moderate

DB00333

Prazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.

Check this interaction

Sodium oxybate

Moderate

DB09072

Prazepam may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.

Check this interaction

Teduglutide

Unknown severity

DB08900

The serum concentration of Prazepam can be increased when it is combined with Teduglutide.

Check this interaction

Yohimbine

Moderate

DB01392

The therapeutic efficacy of Prazepam can be increased when used in combination with Yohimbine.

Check this interaction

Ethanol

Moderate

DB00898

Prazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.

Check this interaction

Azelastine

Moderate

DB00972

Prazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.

Check this interaction

Brimonidine

Moderate

DB00484

Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Prazepam.

Check this interaction

Zimelidine

Unknown severity

DB04832

The risk or severity of adverse effects can be increased when Prazepam is combined with Zimelidine.

Check this interaction

Dapoxetine

Unknown severity

DB04884

The risk or severity of adverse effects can be increased when Prazepam is combined with Dapoxetine.

Check this interaction

Seproxetine

Unknown severity

DB06731

The risk or severity of adverse effects can be increased when Prazepam is combined with Seproxetine.

Check this interaction

Fluvoxamine

Unknown severity

DB00176

The risk or severity of adverse effects can be increased when Prazepam is combined with Fluvoxamine.

Check this interaction

Citalopram

Unknown severity

DB00215

The risk or severity of adverse effects can be increased when Prazepam is combined with Citalopram.

Check this interaction

Duloxetine

Unknown severity

DB00476

The risk or severity of adverse effects can be increased when Prazepam is combined with Duloxetine.

Check this interaction

Trazodone

Unknown severity

DB00656

The risk or severity of adverse effects can be increased when Prazepam is combined with Trazodone.

Check this interaction

Paroxetine

Unknown severity

DB00715

The risk or severity of adverse effects can be increased when Prazepam is combined with Paroxetine.

Check this interaction

Sertraline

Unknown severity

DB01104

The risk or severity of adverse effects can be increased when Prazepam is combined with Sertraline.

Check this interaction

Sibutramine

Unknown severity

DB01105

The risk or severity of adverse effects can be increased when Prazepam is combined with Sibutramine.

Check this interaction

Escitalopram

Unknown severity

DB01175

The risk or severity of adverse effects can be increased when Prazepam is combined with Escitalopram.

Check this interaction

Milnacipran

Unknown severity

DB04896

The risk or severity of adverse effects can be increased when Prazepam is combined with Milnacipran.

Check this interaction

Desvenlafaxine

Unknown severity

DB06700

The risk or severity of adverse effects can be increased when Prazepam is combined with Desvenlafaxine.

Check this interaction

Levomilnacipran

Unknown severity

DB08918

The risk or severity of adverse effects can be increased when Prazepam is combined with Levomilnacipran.

Check this interaction

Indalpine

Unknown severity

DB08953

The risk or severity of adverse effects can be increased when Prazepam is combined with Indalpine.

Check this interaction

Ritanserin

Unknown severity

DB12693

The risk or severity of adverse effects can be increased when Prazepam is combined with Ritanserin.

Check this interaction

Alaproclate

Unknown severity

DB13233

The risk or severity of adverse effects can be increased when Prazepam is combined with Alaproclate.

Check this interaction

Cyproheptadine

Unknown severity

DB00434

The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Prazepam.

Check this interaction

Propiomazine

Unknown severity

DB00777

The risk or severity of CNS depression can be increased when Propiomazine is combined with Prazepam.

Check this interaction

Showing 50 of 801 interactions

Food & lifestyle interactions

Avoid Alcohol

Avoid alcohol.

Avoid Grapefruit

Avoid grapefruit products.

Caffeine Notice

Limit caffeine intake.

Take With Food

Take with food.

Toxicity & overdose

Symptoms of overdose include somnolence, confusion, coma, and diminished reflexes. Respiration, pulse and blood pressure should be monitored.

How it works

Mechanism of action

Prazepam is believed to stimulate GABA receptors in the ascending reticular activating system. Since GABA is inhibitory, receptor stimulation increases inhibition and blocks both cortical and limbic arousal following stimulation of the brain stem reticular formation.

Pharmacodynamics

Prazepam is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant activity. Benzodiazepines may be habit-forming (causing mental or physical dependence), especially when taken for a long time or in high doses.

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Half-life

36-200 hours

Metabolism

Hepatic.

Drug targets(3)

Proteins and enzymes this drug interacts with in the body

Gamma-aminobutyric acid receptor subunit theta

BE0004797

GABRQ

positive allosteric modulator

Specific functionGABA-A receptor activity

Cellular location

Postsynaptic cell membrane

General function & pharmacology

Theta subunit of the heteropentameric ligand-gated chloride channel gated by gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the brain .
PMID:10449790 PMID:16412217
GABA-gated chloride channels, also named GABA(A) receptors (GABAAR), consist of five subunits arranged around a central pore and contain GABA active binding site(s) located at the alpha and beta subunit interfaces (By similarity). When activated by GABA, GABAARs selectively allow the flow of chloride anions across the cell membrane down their electrochemical gradient PMID:10449790 PMID:16412217

Gamma-aminobutyric acid receptor subunit gamma-3

BE0008668

GABRG3

ligand

Specific functionGABA-A receptor activity

Cellular location

Postsynaptic cell membrane

General function & pharmacology

Gamma subunit of the heteropentameric ligand-gated chloride channel gated by gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the brain (By similarity). GABA-gated chloride channels, also named GABA(A) receptors (GABAAR), consist of five subunits arranged around a central pore and contain GABA active binding site(s) located at the alpha and beta subunit interface(s) (By similarity). When activated by GABA, GABAARs selectively allow the flow of chloride across the cell membrane down their electrochemical gradient (By similarity)

Translocator protein

BE0000736

TSPO

modulator

Specific functionandrogen binding

Cellular location

Mitochondrion membrane

General function & pharmacology

Can bind protoporphyrin IX and may play a role in the transport of porphyrins and heme (By similarity). Promotes the transport of cholesterol across mitochondrial membranes and may play a role in lipid metabolism PMID:24814875, but its precise physiological role is controversial. It is apparently not required for steroid hormone biosynthesis.

Was initially identified as peripheral-type benzodiazepine receptor; can also bind isoquinoline carboxamides PMID:1847678

Metabolizing enzymes(1)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

CYP3A4Cytochrome P450 3A4

substrate

ATC classification(1 code)

ATC N05BA11

Affected organisms(1)

Humans and other mammals

International brands(5)

Experimental properties(2)

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Prazepam

DB01588

CAS number

2955-38-6

UNII (FDA)

Q30VCC064M

InChI Key (molecular fingerprint)

MWQCHHACWWAQLJ-UHFFFAOYSA-N

Additional database identifiers

ChEBI

8362

PubChem Compound

4890

PubChem Substance

46505417

KEGG Compound

C07366

KEGG Drug

D00470

ChemSpider

4721

PharmGKB

PA164776668

Therapeutic Targets Database

DAP000689

Wikipedia

Prazepam

ChEMBL

CHEMBL969

ZINC

ZINC000000001971

RxCUI

8627

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4075

GenAtlas

GABRA1

GeneCards

GABRA1

GenBank Gene Database

X13584

GenBank Protein Database

31631

IUPHAR

404

Guide to Pharmacology

404

UniProtKB

P14867

UniProt Accession

GBRA1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4076

GenAtlas

GABRA2

GeneCards

GABRA2

GenBank Gene Database

S62907

GenBank Protein Database

386422

IUPHAR

405

Guide to Pharmacology

405

UniProtKB

P47869

UniProt Accession

GBRA2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4077

GenAtlas

GABRA3

GeneCards

GABRA3

GenBank Gene Database

S62908

GenBank Protein Database

386424

IUPHAR

406

Guide to Pharmacology

406

UniProtKB

P34903

UniProt Accession

GBRA3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4078

GenAtlas

GABRA4

GeneCards

GABRA4

GenBank Gene Database

U30461

GenBank Protein Database

905393

IUPHAR

407

Guide to Pharmacology

407

UniProtKB

P48169

UniProt Accession

GBRA4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4079

GenAtlas

GABRA5

GeneCards

GABRA5

GenBank Gene Database

L08485

GenBank Protein Database

182916

IUPHAR

408

Guide to Pharmacology

408

UniProtKB

P31644

UniProt Accession

GBRA5_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4080

GenAtlas

GABRA6

GeneCards

GABRA6

GenBank Gene Database

S81944

GenBank Protein Database

1470364

IUPHAR

409

Guide to Pharmacology

409

UniProtKB

Q16445

UniProt Accession

GBRA6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4081

GenAtlas

GABRB1

GeneCards

GABRB1

GenBank Gene Database

X14767

GenBank Protein Database

31635

IUPHAR

410

UniProtKB

P18505

UniProt Accession

GBRB1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4082

GenAtlas

GABRB2

GeneCards

GABRB2

GenBank Gene Database

S67368

GenBank Protein Database

455946

IUPHAR

411

UniProtKB

P47870

UniProt Accession

GBRB2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4083

GenAtlas

GABRB3

GeneCards

GABRB3

GenBank Gene Database

M82919

GenBank Protein Database

182925

IUPHAR

412

Guide to Pharmacology

412

UniProtKB

P28472

UniProt Accession

GBRB3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4084

GeneCards

GABRD

GenBank Gene Database

AF016917

GenBank Protein Database

2388693

UniProtKB

O14764

UniProt Accession

GBRD_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4085

GeneCards

GABRE

GenBank Gene Database

U66661

GenBank Protein Database

1857126

UniProtKB

P78334

UniProt Accession

GBRE_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4086

GeneCards

GABRG1

GenBank Gene Database

AK122845

GenBank Protein Database

193783776

UniProtKB

Q8N1C3

UniProt Accession

GBRG1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4087

GeneCards

GABRG2

GenBank Gene Database

X15376

GenBank Protein Database

31637

UniProtKB

P18507

UniProt Accession

GBRG2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4088

GeneCards

GABRG3

GenBank Gene Database

S82769

GenBank Protein Database

1754749

UniProtKB

Q99928

UniProt Accession

GBRG3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4089

GeneCards

GABRP

GenBank Gene Database

U95367

GenBank Protein Database

2197001

UniProtKB

O00591

UniProt Accession

GBRP_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:14454

GeneCards

GABRQ

GenBank Gene Database

AF189259

GenBank Protein Database

7861736

UniProtKB

Q9UN88

UniProt Accession

GBRT_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4075

GenAtlas

GABRA1

GeneCards

GABRA1

GenBank Gene Database

X13584

GenBank Protein Database

31631

IUPHAR

404

Guide to Pharmacology

404

UniProtKB

P14867

UniProt Accession

GBRA1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4076

GenAtlas

GABRA2

GeneCards

GABRA2

GenBank Gene Database

S62907

GenBank Protein Database

386422

IUPHAR

405

Guide to Pharmacology

405

UniProtKB

P47869

UniProt Accession

GBRA2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4077

GenAtlas

GABRA3

GeneCards

GABRA3

GenBank Gene Database

S62908

GenBank Protein Database

386424

IUPHAR

406

Guide to Pharmacology

406

UniProtKB

P34903

UniProt Accession

GBRA3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4079

GenAtlas

GABRA5

GeneCards

GABRA5

GenBank Gene Database

L08485

GenBank Protein Database

182916

IUPHAR

408

Guide to Pharmacology

408

UniProtKB

P31644

UniProt Accession

GBRA5_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4086

GeneCards

GABRG1

GenBank Gene Database

AK122845

GenBank Protein Database

193783776

UniProtKB

Q8N1C3

UniProt Accession

GBRG1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4087

GeneCards

GABRG2

GenBank Gene Database

X15376

GenBank Protein Database

31637

UniProtKB

P18507

UniProt Accession

GBRG2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4088

GeneCards

GABRG3

GenBank Gene Database

S82769

GenBank Protein Database

1754749

UniProtKB

Q99928

UniProt Accession

GBRG3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1158

GenAtlas

TSPO

GeneCards

TSPO

GenBank Gene Database

M36035

GenBank Protein Database

306883

Guide to Pharmacology

2879

UniProtKB

P30536

UniProt Accession

TSPO_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2637

GenAtlas

CYP3A4

GeneCards

CYP3A4

GenBank Gene Database

M18907

Guide to Pharmacology

1337

UniProtKB

P08684

UniProt Accession

CP3A4_HUMAN

International reference pricing

2 formulations

Reference pricing from DrugBank. Prices are indicative and may not reflect current UK costs.

From $3.37/tablet

To $3.41/tablet

Doral 7.5 mg tablet

$3.37/tablet

Doral 15 mg tablet

$3.41/tablet

Source: DrugBank. Used under CC BY-NC 4.0 academic licence for non-commercial purposes.

DrugBank citations

If you use DrugBank data in your research, please cite the following publications:

Knox C., Wilson M., Klinger C.M., et al

DrugBank 6.

0: the DrugBank Knowledgebase for 2024

Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275

PMID: 37953279

Wishart D.S., Feunang Y.D., Guo A.C., et al

DrugBank 5.

0: a major update to the DrugBank database for 2018

Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082

PMID: 29126136

Show earlier publications

Law V., Knox C., Djoumbou Y., et al

DrugBank 4.

0: shedding new light on drug metabolism

Nucleic Acids Res. 2014 Jan 142(1):D1091-7

PMID: 24203711

Knox C., Law V., Jewison T., et al

DrugBank 3.

0: a comprehensive resource for 'omics' research on drugs

Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41

PMID: 21059682

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Research

2008 Jan36(Database issue):D901-6

PMID: 18048412

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Research

2006 Jan 134(Database issue):D668-72

PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated about 1 month ago(4 Mar 2026)

Back to medicines

Prazepam 10mg tablets

Legal requirements

Other medicines in this category

Safety monitoring data

Yellow Card reports

EudraVigilance

British National Formulary

Pharmacy stock checkers

Supply & product information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Half-life

Metabolism

Clinical essentials

Pharmacology

Deep science
4

Chemical identifiers

Prazepam

Additional database identifiers

International reference pricing

DrugBank citations

Prazepam 10mg tablets

Controlled drug information

Legal requirements

Other medicines in this category

Safety & regulatory

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

Medicines like this

Guidance (NICE / BNF)

British National Formulary

Availability, stocks & shortages

Pharmacy stock checkers

Supply & product information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

DrugBank data

Key facts

Pharmacokinetics at a glance

Half-life

Metabolism

Clinical essentials

Pharmacology

Deep science4

Chemical identifiers

Prazepam

Additional database identifiers

International reference pricing

DrugBank citations

Deep science
4